Technological projects portfolio
GLIOVED
First-in-class chemical entity to fight glioblastoma
Investment: €720k
Scope: Healthcare
Scientific field(s): Biology and medicinal chemistry
Institution(s): CNRS - Inserm - Université de Nice
Development: Technology to be marketed
USE CASES
Glioblastoma is the most well-known form of primary tumor of the brain.
It affects adults of all ages and is resistant to current treatments, which leads to patient death within 18 months.
There is a true need for new therapeutic strategies.
ADVANTAGES
The GLIOVED project is based on the identification of new derivatives of natural plant products (of the Euphorbiaceae family) that act on a new biological target.
The purpose of GLIOVED is therefore to develop a first-in-class therapy using these natural products.
The strength of the project lies in the association of chemists, biologists specialized in the target and glioblastoma specialists to optimize the various steps of drug discovery.
APPLICATIONS
The GLIOVED project aims to develop a candidate medication, mainly for the treatment of glioblastoma, for use as first-line treatment in combination with the reference treatment.
Other indications may be considered: treatment of kidney cancer, myeloma, certain forms of leukemia, etc.
